Nautilus Biotechnology Q2 EPS $(0.13) Beats $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Nautilus Biotechnology reported Q2 losses of $(0.13) per share, beating the analyst consensus estimate of $(0.17) by 23.53 percent. However, this represents an 8.33 percent increase in losses compared to the same period last year.
August 04, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Nautilus Biotechnology's Q2 earnings beat estimates but showed an increase in losses YoY. This mixed result could lead to uncertain market reactions.
Nautilus Biotechnology's Q2 earnings beat analyst estimates, which is generally a positive signal for investors. However, the increase in losses compared to the same period last year could be a cause for concern, leading to a neutral score.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100